Phase 3 trial evaluates the efficacy of pegylated liposomal doxorubicin in patients with desmoid tumors, suggesting improved treatment options.
Desmoid tumours are a locally invasive neoplasm that can exhibit unpredictable clinical behaviour. While treatment options are numerous, few are supported by level 1 evidence. A recent phase 3 trial evaluated the efficacy of long-used pegylated liposomal doxorubicin in patients with progressive desmoid tumours.
No takes yet. Share an insight, caveat, or question.
Dossa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: